Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Lipson

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Therapeutic Advances in Respiratory Disease|November 10, 2020
Impact of baseline COPD symptom severity on the benefit from dual <i>versus</i> mono-bronchodilators: an analysis of the EMAX randomised controlled trialClaus F Vogelmeier, Edward M Kerwin, Leif H Bjermer, et al.
Magnetic Resonance in Medicine|February 28, 2007
Hyperpolarized 13C MRI of the pulmonary vasculature and parenchymaMasaru Ishii, Kiarash Emami, Stephen Kadlecek, et al.
Magnetic Resonance in Medicine|July 12, 2002
Pulmonary ventilation and perfusion scanning using hyperpolarized helium-3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patientsDavid A Lipson, David A Roberts, John Hansen-Flaschen, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 14, 2022
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT TrialJ Michael Wells, Gerard J Criner, David M G Halpin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 8, 2022
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL TrialReynold A Panettieri, Carlos A Camargo, Tariq Cheema, et al.
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
NPJ Primary Care Respiratory Medicine|May 26, 2021
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPDSandeep Bansal, Martin Anderson, Antonio Anzueto, et al.
Critical Care Medicine|June 24, 2015
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress SyndromeJason D Christie, Steven Vaslef, Philip K Chang, et al.
Thorax|January 31, 2012
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRIHelen Marshall, Martin H Deppe, Juan Parra-Robles, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Respiratory Disease|November 10, 2020
Impact of baseline COPD symptom severity on the benefit from dual <i>versus</i> mono-bronchodilators: an analysis of the EMAX randomised controlled trialClaus F Vogelmeier, Edward M Kerwin, Leif H Bjermer, et al.
Magnetic Resonance in Medicine|February 28, 2007
Hyperpolarized 13C MRI of the pulmonary vasculature and parenchymaMasaru Ishii, Kiarash Emami, Stephen Kadlecek, et al.
Magnetic Resonance in Medicine|July 12, 2002
Pulmonary ventilation and perfusion scanning using hyperpolarized helium-3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patientsDavid A Lipson, David A Roberts, John Hansen-Flaschen, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 14, 2022
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT TrialJ Michael Wells, Gerard J Criner, David M G Halpin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 8, 2022
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL TrialReynold A Panettieri, Carlos A Camargo, Tariq Cheema, et al.
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
NPJ Primary Care Respiratory Medicine|May 26, 2021
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPDSandeep Bansal, Martin Anderson, Antonio Anzueto, et al.
Critical Care Medicine|June 24, 2015
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress SyndromeJason D Christie, Steven Vaslef, Philip K Chang, et al.
Thorax|January 31, 2012
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRIHelen Marshall, Martin H Deppe, Juan Parra-Robles, et al.
Pageof 12